PURPOSE: The purpose of this study is to develop a brief measure of problem areas experienced by patients following primary treatment for breast cancer. METHOD: Systematic reviews of the quantitative and qualitative literature were used to inform selection of scale items using (1) valid and reliable items from a national item bank (patient reported outcomes measurement information system [PROMIS]), (2) existing scales from prior breast cancer survivorship research, or (3) items developed by the investigators. RESULTS: Participants (n = 400) were on average 51 years old, highly educated, Caucasian, diagnosed with stage I-III breast cancer, and a median of 1.96 years post-primary treatment. Principal component analysis on a random sample (n = 200) and confirmation on a second random sample (n = 200) indicated that each of the scales under consideration provided a significant measurement model for the symptom burden (CFI = 0.95), health behavior (CFI = 1.00), functional limitation (CFI = 0.99), health care seeking skill (CFI = 0.98), and cancer-related financial strain (CFI = 1.00) broad domains. The median Cronbach's alpha was 0.91. The measure demonstrated convergent, divergent, construct, and clinical validity. Lower levels of fatigue (β = 0.251. p < 0.000) and pain (β = 0.221, p < 0.000) and greater health competence (β = 0.278, p < 0.000) and physical activity (β = 0.165, p < 0.000) were associated with self-rated global health (F = 60.43, p < 0.000). The final measure consists of 73 items and requires approximately 15 min to complete. DISCUSSION: The Cancer Survivor Profile (CSPro) provides a profile of problem areas supported by epidemiological and qualitative research on unmet needs of breast cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Breast cancer survivors can use the CSPro to prioritize problem areas following cancer treatment.
PURPOSE: The purpose of this study is to develop a brief measure of problem areas experienced by patients following primary treatment for breast cancer. METHOD: Systematic reviews of the quantitative and qualitative literature were used to inform selection of scale items using (1) valid and reliable items from a national item bank (patient reported outcomes measurement information system [PROMIS]), (2) existing scales from prior breast cancer survivorship research, or (3) items developed by the investigators. RESULTS:Participants (n = 400) were on average 51 years old, highly educated, Caucasian, diagnosed with stage I-III breast cancer, and a median of 1.96 years post-primary treatment. Principal component analysis on a random sample (n = 200) and confirmation on a second random sample (n = 200) indicated that each of the scales under consideration provided a significant measurement model for the symptom burden (CFI = 0.95), health behavior (CFI = 1.00), functional limitation (CFI = 0.99), health care seeking skill (CFI = 0.98), and cancer-related financial strain (CFI = 1.00) broad domains. The median Cronbach's alpha was 0.91. The measure demonstrated convergent, divergent, construct, and clinical validity. Lower levels of fatigue (β = 0.251. p < 0.000) and pain (β = 0.221, p < 0.000) and greater health competence (β = 0.278, p < 0.000) and physical activity (β = 0.165, p < 0.000) were associated with self-rated global health (F = 60.43, p < 0.000). The final measure consists of 73 items and requires approximately 15 min to complete. DISCUSSION: The Cancer Survivor Profile (CSPro) provides a profile of problem areas supported by epidemiological and qualitative research on unmet needs of breast cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Breast cancer survivors can use the CSPro to prioritize problem areas following cancer treatment.
Authors: Susan L Beck; Anna L Schwartz; Gail Towsley; William Dudley; Andrea Barsevick Journal: J Pain Symptom Manage Date: 2004-02 Impact factor: 3.612
Authors: Danielle Blanch-Hartigan; Laura P Forsythe; Catherine M Alfano; Tenbroeck Smith; Larissa Nekhlyudov; Patricia A Ganz; Julia H Rowland Journal: J Clin Oncol Date: 2014-04-21 Impact factor: 44.544
Authors: Julienne E Bower; Kate Bak; Ann Berger; William Breitbart; Carmelita P Escalante; Patricia A Ganz; Hester Hill Schnipper; Christina Lacchetti; Jennifer A Ligibel; Gary H Lyman; Mohammed S Ogaily; William F Pirl; Paul B Jacobsen Journal: J Clin Oncol Date: 2014-04-14 Impact factor: 44.544
Authors: Carlos A Celis-Morales; Francisco Perez-Bravo; Luis Ibañez; Carlos Salas; Mark E S Bailey; Jason M R Gill Journal: PLoS One Date: 2012-05-09 Impact factor: 3.240
Authors: Andy S K Cheng; Xiangyu Liu; Peter H F Ng; Cindy T T Kwok; Yingchun Zeng; Michael Feuerstein Journal: BMJ Open Date: 2020-07-05 Impact factor: 2.692
Authors: Xiaofan Bu; Peter H F Ng; Qi Chen; Andy S K Cheng; Wenjing Xu; Ying Tong; Qingping Tang; Xiangyu Liu Journal: BMJ Open Date: 2022-02-16 Impact factor: 2.692
Authors: Xiaofan Bu; Peter Hf Ng; Wenjing Xu; Qinqin Cheng; Peter Q Chen; Andy Sk Cheng; Xiangyu Liu Journal: JMIR Serious Games Date: 2022-02-28 Impact factor: 3.364
Authors: Xiaofan Bu; Cai Jin; Rongrong Fan; Andy S K Cheng; Peter H F Ng; Yimin Xia; Xiangyu Liu Journal: BMC Cancer Date: 2022-02-03 Impact factor: 4.430